Only as available as its most restricted ingredient, both members are on the FDA's review agenda, so the stack is not yet available.
Wolverine stack
What people mean by “Wolverine”: BPC-157 paired with TB-500, two research peptides combined for tissue repair, named after the comic-book healing factor. It's a community nickname, not a clinical designation.
Last reviewed June 16, 2026.
The honest answer
The Wolverine stack pairs two peptides studied for different parts of repair, BPC-157 for local tissue effects and TB-500 for systemic ones. The idea is that they cover more of the healing process together than either does alone. Almost everything known about either comes from animal studies, and the combination itself has never been tested in people.
- In animal models, BPC-157 has shown effects on angiogenesis, growth-factor signaling, and tendon and gut healing.
- TB-500, a thymosin β-4 fragment, has shown cell-migration and anti-inflammatory effects in preclinical work.
- The two are studied for overlapping parts of the repair process, which is the mechanistic basis for pairing them.
- There are no human randomized controlled trials of the combination.
- No completed phase 2/3 trials exist for either peptide on its own for tissue repair.
- The evidence is almost entirely from rodents.
- The synergy story is a hypothesis, not a proven result.
Go deeper
BPC-157 is usually described as a “local” actor, studied for effects at the site of injury, like tendon, ligament, and gut lining. TB-500 is described as a more “systemic” actor, a fragment of a protein involved in cell migration and tissue organization throughout the body. The community pairs them on the theory that one covers local repair while the other covers system-wide signaling, so together they touch more of the healing process than either alone. That's the concept, and it is reasoning by mechanism, not a result proven in people. It also says nothing about how anyone should actually use them: that is a clinical decision, not something a web page should script.
We explain what the Wolverine stack is and what the evidence shows. We don't publish doses, ratios, or how-to, any plan comes from a licensed clinician.
The pattern to notice: every step up the ladder adds a peptide, and every added peptide adds variables without adding combination evidence. More compounds means more unknowns, not more proof.
| Stack | What it adds | Combination evidence |
|---|---|---|
| WolverineBPC-157 + TB-500 | The base repair pair | Animal-model data on each member; none on the combination |
| GLOW+ GHK-Cu | A copper peptide, tilting toward skin and appearance | Even less combination evidence than Wolverine |
| KLOW+ KPV | An anti-inflammatory, gut-leaning peptide | The least combination evidence of the three |
Status & access
Both BPC-157 and TB-500 were removed from FDA Category 2 in April 2026, which is not approval, and not 503A Bulks-List eligibility, and both are on the FDA's PCAC agenda for July 23, 2026 (advisory only). Both are prohibited in competition under WADA.
Compounded medications are prepared for an individual patient and are not FDA-approved. Removal from FDA Category 2 (April 2026) is not approval and not 503A Bulks-List eligibility. PCAC is advisory, a favorable vote leads to rulemaking, not instant availability.
We explain what the Wolverine stack is and what the evidence shows. We don't publish doses, ratios, or how-to, any plan comes from a licensed clinician.
Questions, answered first
What is the Wolverine stack?
The Wolverine stack is the community nickname for BPC-157 combined with TB-500, two research peptides paired for tissue repair, named after the comic-book healing factor. It's a nickname, not a clinical protocol, and the combination has never been tested in a human trial.
Is the Wolverine stack legal in 2026?
Neither peptide is available to prescribe today. Both were removed from FDA Category 2 in April 2026, which is not the same as approval or 503A Bulks-List eligibility, and both go before the FDA's PCAC on July 23, 2026. PCAC is advisory: a favorable vote starts rulemaking, not instant availability. Compounded medications are not FDA-approved.
Wolverine vs GLOW vs KLOW, what's the difference?
They form an escalation ladder. Wolverine is the base pair (BPC-157 + TB-500); GLOW adds a copper peptide (GHK-Cu) for skin; KLOW adds KPV on top. The honest catch: each step adds a peptide and therefore more unknowns, GLOW and KLOW have even less combination evidence than Wolverine, and none of the three has human combination-trial data.